Eyebright Historical Cash Flow
| 688050 Stock | 90.61 1.90 2.05% |
Analysis of Eyebright Medical cash flow over time is an excellent tool to project Eyebright Medical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 234.5 M or Depreciation of 80.6 M as it is a great indicator of Eyebright Medical ability to facilitate future growth, repay debt on time or pay out dividends.
Eyebright |
About Eyebright Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Eyebright balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Eyebright's non-liquid assets can be easily converted into cash.
Eyebright Medical Cash Flow Chart
Add Fundamental
Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Eyebright Medical value has been used up. For tax purposes Eyebright Medical can deduct the cost of the tangible assets it purchases as business expenses. However, Eyebright Medical Technology must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most accounts from Eyebright Medical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Eyebright Medical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Eyebright Medical Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Eyebright Medical's Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Depreciation is expected to grow to about 80.6 M, whereas Change To Inventory is projected to grow to (80.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Non Cash Items | 8.4M | 18.8M | 19.3M | 12.8M | Depreciation | 32.0M | 43.3M | 76.7M | 80.6M |
Eyebright Medical cash flow statement Correlations
Click cells to compare fundamentals
Eyebright Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eyebright Medical cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (24.4M) | 1.7M | 3.3M | (22.8M) | (85.1M) | (80.9M) | |
| Change In Cash | 129.4M | 340.5M | (64.0M) | (122.8M) | 181.8M | 190.8M | |
| Free Cash Flow | (91.1M) | 4.6M | (91.9M) | (20.9M) | (157.7M) | (149.8M) | |
| Change In Working Capital | (39.6M) | (137.1K) | 11.1M | (39.3M) | (177.9M) | (169.0M) | |
| Begin Period Cash Flow | 67.0M | 196.3M | 536.8M | 472.9M | 350.0M | 234.5M | |
| Other Cashflows From Financing Activities | 22.9M | 805.2M | 168.3M | (17.0M) | (19.6M) | (18.6M) | |
| Depreciation | 22.4M | 26.7M | 32.0M | 43.3M | 76.7M | 80.6M | |
| Other Non Cash Items | 1.9M | 707.8K | 8.4M | 18.8M | 19.3M | 12.8M | |
| Dividends Paid | 265.0K | 13.0K | 30.5M | 44.4M | 61.4M | 64.4M | |
| Capital Expenditures | 141.6M | 118.7M | 311.2M | 271.0M | 370.3M | 388.9M | |
| Total Cash From Operating Activities | 50.5M | 123.4M | 219.3M | 250.1M | 212.6M | 122.2M | |
| Net Income | 65.8M | 96.1M | 167.8M | 227.2M | 304.4M | 319.7M | |
| Total Cash From Financing Activities | 14.9M | 804.7M | 137.7M | (65.1M) | (74.8M) | (71.1M) | |
| End Period Cash Flow | 196.3M | 536.8M | 472.9M | 350.0M | 531.8M | 306.3M |
Currently Active Assets on Macroaxis
Other Information on Investing in Eyebright Stock
The Cash Flow Statement is a financial statement that shows how changes in Eyebright balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Eyebright's non-liquid assets can be easily converted into cash.